Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
about
Prospects for vaccine prevention of meningococcal infectionEstimates of the burden of meningococcal disease in Italy: implications for prevention and controlImpact of a physician recommendationImportance of circulating antibodies in protection against meningococcal diseaseStructural and Kinetic Characterizations of the Polysialic Acid O-Acetyltransferase OatWY from Neisseria meningitidisAn evaluation of emerging vaccines for childhood meningococcal diseaseInfections of People with Complement Deficiencies and Patients Who Have Undergone SplenectomyPersistence of serogroup C antibody responses following quadrivalent meningococcal conjugate vaccination in United States military personnel.The association of meningococcal disease with influenza in the United States, 1989-2009.Epidemiology, diagnosis, and antimicrobial treatment of acute bacterial meningitis.Invasive meningococcal disease epidemiology and control measures: a framework for evaluationImplications for registry-based vaccine effectiveness studies from an evaluation of an immunization registry: a cross-sectional study.CD14 C-159T and toll-like receptor 4 Asp299Gly polymorphisms in surviving meningococcal disease patientsUptake of meningococcal conjugate vaccine among adolescents in large managed care organizations, United States, 2005: demand, supply and seasonality.Epidemiological profile of meningococcal disease in the United StatesGuidelines for the Prevention and Treatment of Opportunistic Infections among HIV-exposed and HIV-infected children: recommendations from CDC, the National Institutes of Health, the HIV Medicine Association of the Infectious Diseases Society of AmerPopulation structure and capsular switching of invasive Neisseria meningitidis isolates in the pre-meningococcal conjugate vaccine era--United States, 2000-2005Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaPhase I/II, open-label trial of safety and immunogenicity of meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine in human immunodeficiency virus-infected adolescents.Cluster of serogroup W135 meningococci, southeastern Florida, 2008-2009.Assessing the risk of laboratory-acquired meningococcal disease.Vaccine herd effect.Middle- and high-school health education regarding adolescent vaccines and human papillomavirus.Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of theUnderstanding attitudes toward adolescent vaccination and the decision-making dynamic among adolescents, parents and providers.Estimating costs associated with a community outbreak of meningococcal disease in a colombian Caribbean city.Correlates of receiving recommended adolescent vaccines among adolescent females in North Carolina.Characterization of DsbD in Neisseria meningitidis.Validity of parent-reported vaccination status for adolescents aged 13-17 years: National Immunization Survey-Teen, 2008.Using the North Dakota Immunization Information System to determine adolescent vaccination rates and uptake.Vaccination coverage among U.S. adolescents aged 13-17 years eligible for the Vaccines for Children program, 2009.Critical appraisal of a quadrivalent CRM(197) conjugate vaccine against meningococcal serogroups A, C W-135 and Y (Menveo) in the context of treatment and prevention of invasive diseaseMeningococcal glycoconjugate vaccines.Vaccination policy in Korean armed forces: current status and future challengeMeningococcal conjugate vaccines: optimizing global impact.Safety and immunogenicity of quadrivalent meningococcal conjugate vaccine in 2- to 10-year-old human immunodeficiency virus-infected children.NCI, NHLBI/PBMTC first international conference on late effects after pediatric hematopoietic cell transplantation: persistent immune deficiency in pediatric transplant survivorsSequence Type 4821 Clonal Complex Serogroup B Neisseria meningitidis in China, 1978-2013.Immunogenicity and safety of meningococcal C conjugate vaccine in children and adolescents infected and uninfected with HIV in Rio de Janeiro, Brazil.Neisseria Base: a comparative genomics database for Neisseria meningitidis.
P2860
Q24537338-2FE8D934-633D-46AF-A464-763DAECD74BBQ26770711-DB196A4F-AF79-4C42-A75D-08094150C545Q26779507-9BF04D48-C95F-4E74-B9FE-E67EE547B331Q27023516-620FA289-C6B4-4495-A84C-D1112F7690BDQ27655942-A6C5074F-1E0E-4857-8E61-382E32BF1E09Q28741833-E6F8F384-9CCD-4344-8B89-77AD1BA6713CQ28972389-48B205F7-9925-4A20-A8AE-8B318F68B414Q30210120-98026B3F-B96B-4C62-AC5A-132E95B67D6AQ30367269-35F7B10C-6A69-4042-9FC8-AF3826877D93Q30431534-6E7303DA-20E8-465C-9B3E-64D99DE0BFFFQ33289528-8B5AD498-4BFF-4D09-A755-3E966A0F3C9FQ33334661-7A209FB4-479C-4367-8103-6DB4DF83625DQ33509021-7122E800-94E1-47BA-9CB2-F58354563A2DQ33514762-D0BED031-9354-40B4-A4DB-49723BD2302EQ33648635-3C93FF1B-D34C-4937-9466-DC2B4B66831CQ33650105-DF95128E-C69E-475F-80C2-D8E383D8AF79Q33729202-8F288F3D-35C9-45E8-9944-608D324426F1Q33768673-41E8A043-8EA7-4F8C-A8E4-8CB87F30D76CQ33844571-88FFC8B1-717E-4DAC-B35E-CFDB3BC07B21Q33868289-2B690F4C-5A7D-402A-8DB1-F9609365364BQ34042370-2894BA6A-DAC2-4A70-B685-629BAACEB285Q34186752-596355F6-2160-4747-B70F-442A346E05D0Q34197043-17DAFDB4-8F26-46E3-9C9D-FBEEDC7DC5BFQ34212799-0291EE6A-CE12-44B1-872A-DEA4312C5879Q34329277-B0D875F1-5D00-414D-A4C0-C9EC3B584294Q34458576-7D8523CF-ACE8-48D7-96BB-7C32CE8F426DQ34706918-68C14A96-3358-452F-9CD6-A8F3414EC697Q34939544-0B215A33-0AF4-44FC-9CC8-8AF130ACE0B1Q35040468-B0D5EB8A-EF41-47FD-8C79-E6F57AC9064AQ35040474-AC557925-4B6F-4644-9C75-157DBEA1D9DCQ35040492-8CA12040-5842-4539-8648-1BBD3795388DQ35187182-6E355127-73E0-427F-A135-3EDE1877AE5EQ35194824-C4B94ADF-4064-4860-B9AB-23B04C362838Q35198526-1AFCF389-DAB3-46E1-8E8E-799196D466B3Q35547767-DB4862E6-C466-48C0-928C-909E5D6DD0D0Q35655927-D44F8620-DA64-4203-B53C-BE8087D32729Q35661304-561DE3B8-2E2C-4E9D-B410-D28342C39973Q35673367-E913BF92-3569-4E0C-8A8D-3CCA31CFC125Q35680467-AB9D3534-9018-476A-91AE-C794E85335A9Q35687415-5BD10544-DFA4-4D6B-9DB6-713C36D0C253
P2860
Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP)
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Prevention and control of meni ...... Immunization Practices (ACIP)
@ast
Prevention and control of meni ...... Immunization Practices (ACIP)
@en
Prevention and control of meni ...... Immunization Practices (ACIP)
@nl
type
label
Prevention and control of meni ...... Immunization Practices (ACIP)
@ast
Prevention and control of meni ...... Immunization Practices (ACIP)
@en
Prevention and control of meni ...... Immunization Practices (ACIP)
@nl
prefLabel
Prevention and control of meni ...... Immunization Practices (ACIP)
@ast
Prevention and control of meni ...... Immunization Practices (ACIP)
@en
Prevention and control of meni ...... Immunization Practices (ACIP)
@nl
P1476
Prevention and control of meni ...... Immunization Practices (ACIP)
@en
P2093
National Center for Infectious Diseases, Centers for Disease Control and Prevention (CDC)
Oleg O Bilukha
P407
P577
2005-05-01T00:00:00Z